PHOSPHODIESTERASE TYPE-IV INHIBITION - STRUCTURE-ACTIVITY-RELATIONSHIPS OF 1,3-DISUBSTITUTED PYRROLIDINES

被引:28
作者
FELDMAN, PL
BRACKEEN, MF
COWAN, DJ
MARRON, BE
SCHOENEN, FJ
STAFFORD, JA
SUH, EM
DOMANICO, PL
ROSE, D
LEESNITZER, MA
BRAWLEY, ES
STRICKLAND, AB
VERGHESE, MW
CONNOLLY, KM
BATEMANFITE, R
NOEL, LS
SEKUT, L
STIMPSON, SA
机构
[1] GLAXO INC,RES INST,DEPT BIOCHEM,RES TRIANGLE PK,NC 27709
[2] GLAXO INC,RES INST,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709
[3] GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709
关键词
D O I
10.1021/jm00009a011
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis of 1,3-disubstituted pyrrolidines 2 and their activities as type IV phosphodiesterase (PDE) inhibitors are described. Various groups were appended to the nitrogen of the pyrrolidine nucleus to enable structure-activity relationships to be assessed. Groups which render the pyrrolidine nitrogen of 2 nonbasic yielded potent PDE-IV inhibitors. Analogs of amides, carbamates, and ureas of 2 were synthesized to determine the effects that substitution on these functional groups had on PDE-IV inhibitor potency. The structural requirements for PDE-IV inhibitor potency differed among the three classes. A representative amide, carbamate, and urea (2c,d,h) were shown to be >50-fold selective for inhibiting PDE-IV versus representative PDEs from families I-III and V. Furthermore, these same three inhibitors demonstrated potent functional activity (IC50 < 1 mu M) by inhibiting tumor necrosis factor-alpha (TNF-alpha) release from lipopolysaccharide (LPS)-activated purified human peripheral blood monocytes and mouse peritoneal macrophages. These compounds were also tested orally in LPS-injected mice and demonstrated dose-dependent inhibition of serum TNF-alpha levels.
引用
收藏
页码:1505 / 1510
页数:6
相关论文
共 26 条
[1]   SELECTIVE TYPE-IV PHOSPHODIESTERASE INHIBITORS AS ANTIASTHMATIC AGENTS - THE SYNTHESES AND BIOLOGICAL-ACTIVITIES OF 3-(CYCLOPENTYLOXY)-4-METHOXYBENZAMIDES AND ANALOGS [J].
ASHTON, MJ ;
COOK, DC ;
FENTON, G ;
KARLSSON, JA ;
PALFREYMAN, MN ;
RAEBURN, D ;
RATCLIFFE, AJ ;
SOUNESS, JE ;
THURAIRATNAM, S ;
VICKER, N .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (11) :1696-1703
[2]   THE CRYSTAL-STRUCTURE, ABSOLUTE-CONFIGURATION, AND PHOSPHODIESTERASE INHIBITORY ACTIVITY OF (+)-1-(4-BROMOBENZYL)-4-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)-PYRROLIDIN-2-ONE [J].
BAURES, PW ;
EGGLESTON, DS ;
ERHARD, KF ;
CIESLINSKI, LB ;
TORPHY, TJ ;
CHRISTENSEN, SB .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (22) :3274-3277
[3]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[4]  
BEELEY, 1993, Patent No. 9325517
[5]   A FAMILY OF HUMAN PHOSPHODIESTERASES HOMOLOGOUS TO THE DUNCE LEARNING AND MEMORY GENE-PRODUCT OF DROSOPHILA-MELANOGASTER ARE POTENTIAL TARGETS FOR ANTIDEPRESSANT DRUGS [J].
BOLGER, G ;
MICHAELI, T ;
MARTINS, T ;
STJOHN, T ;
STEINER, B ;
RODGERS, L ;
RIGGS, M ;
WIGLER, M ;
FERGUSON, K .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (10) :6558-6571
[6]   INHIBITION OF EOSINOPHIL CYCLIC-NUCLEOTIDE PDE ACTIVITY AND OPSONISED ZYMOSAN-STIMULATED RESPIRATORY BURST BY TYPE-IV-SELECTIVE PDE INHIBITORS [J].
DENT, G ;
GIEMBYCZ, MA ;
RABE, KF ;
BARNES, PJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (02) :1339-1346
[7]   PROSPECTS FOR SELECTIVE CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF BRONCHIAL-ASTHMA [J].
GIEMBYCZ, MA ;
DENT, G .
CLINICAL AND EXPERIMENTAL ALLERGY, 1992, 22 (03) :337-344
[8]   EFFECTS OF NOVEL CATECHOL ETHER IMIDAZOLIDINONES ON CALCIUM-INDEPENDENT PHOSPHODIESTERASE ACTIVITY, [H-3] ROLIPRAM BINDING, AND RESERPINE-INDUCED HYPOTHERMIA IN MICE [J].
KOE, BK ;
LEBEL, LA ;
NIELSEN, JA ;
RUSSO, LL ;
SACCOMANO, NA ;
VINICK, FJ ;
WILLIAMS, IH .
DRUG DEVELOPMENT RESEARCH, 1990, 21 (02) :135-142
[9]  
LOMBARDO L, 1992, Patent No. 923039176
[10]  
LOMBARDO L, 1991, Patent No. 913071973